Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Obstetricia y Ginecología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Open-label Comparative Study of Standard Whole Brain Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Women With Brain Metastases From Breast Cancer
INTERVENTIONAL
Inicio: 1 de feb de 2004
ID: NCT00083304
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)
INTERVENTIONAL
Inicio: 18 de jun de 2021
ID: NCT04895358
Completado
Fase 3
ClinicalTrials.gov
Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma
INTERVENTIONAL
Inicio: 1 de dic de 2010
ID: NCT01239732
Reclutando
Fase 3
ClinicalTrials.gov
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer
INTERVENTIONAL
Inicio: 24 de jul de 2025
ID: NCT06757634
Completado
Fase 3
ClinicalTrials.gov
An Open-Label, Phase IIIb, Single Arm, Multicenter Safety Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
INTERVENTIONAL
Inicio: 10 de dic de 2019
ID: NCT04148911
Completado
Fase 3
ClinicalTrials.gov
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
INTERVENTIONAL
Inicio: 1 de oct de 2009
ID: NCT01007942
Completado
Fase 3
ClinicalTrials.gov
A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant
INTERVENTIONAL
Inicio: 1 de sept de 2003
ID: NCT00080301
Reclutando
Fase 3
ClinicalTrials.gov
A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
INTERVENTIONAL
Inicio: 10 de may de 2021
ID: NCT04862663
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
INTERVENTIONAL
Inicio: 30 de jun de 2025
ID: NCT06966700
Completado
Fase 3
ClinicalTrials.gov
Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 µg/24h and 16 µg/24h) of the Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) for a Maximum of 3 Years in Women 18 to 35 Years of Age and an Extension Phase of the 16µg/24h Dose Group (LCS16 Arm) up to 5 Years
INTERVENTIONAL
Inicio: 1 de ago de 2007
ID: NCT00528112
Completado
ClinicalTrials.gov
The CHIPS Trial (Control of Hypertension In Pregnancy Study)
INTERVENTIONAL
Inicio: 1 de abr de 2009
ID: NCT01192412
Reclutando
ClinicalTrials.gov
International Prospective REgistry on Pre-pectorAl Breast REconstruction
OBSERVATIONAL
Inicio: 12 de sept de 2023
ID: NCT05817175
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor- Positive Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 9 de dic de 2003
ID: NCT00073528
Activo, no recluta
Fase 2
ClinicalTrials.gov
PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY
INTERVENTIONAL
Inicio: 16 de sept de 2020
ID: NCT04553133
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III Randomised Clinical Trial Comparing Sentinel Node Biopsy With No Retroperitoneal Node Dissection in Apparent Early-Stage Endometrial Cancer
INTERVENTIONAL
Inicio: 18 de ene de 2021
ID: NCT04073706
Aún no recluta
ClinicalTrials.gov
Lateral Cord Electrical Stimulation Can Improve Spasticity in Chronic Spastic Cerebral Palsy
INTERVENTIONAL
Inicio: 1 de jun de 2025
ID: NCT02199015
Completado
Fase 3
ClinicalTrials.gov
A Multi-centre, Randomized, Double-blind, Active Control, Parallel-group, 2-arm Study to Investigate the Effect of Ethinylestradiol / Drospirenone (0.02 mg/3 mg) Oral Contraception in a 24/4 Regimen Compared to Ethinylestradiol / Desogestrel (0.02 mg/0.15 mg) Oral Contraception in a 21/7 Regimen on Hormone Withdrawal Associated Symptoms in Otherwise Healthy Women After 4 Cycles of Treatment
INTERVENTIONAL
Inicio: 1 de abr de 2010
ID: NCT01076582
Reclutando
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).
INTERVENTIONAL
Inicio: 6 de ago de 2025
ID: NCT06952803
Completado
ClinicalTrials.gov
The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis
OBSERVATIONAL
Inicio: 15 de oct de 2011
ID: NCT01285479
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
INTERVENTIONAL
Inicio: 11 de jun de 2019
ID: NCT03822468
Anterior
1
...
9
10
11
...
434
Siguiente
Filtros